SK Biopharm, 2Q Sales Increase 1060%... Operating Loss Widens
[Asia Economy Reporter Ji Yeon-jin] SK Biopharm announced on the 10th that its consolidated sales for the second quarter reached 23.9 billion KRW, a 1060% increase compared to the same period last year.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- Central Labor Relations Commission Chair: "Mediation Proposal Unlikely Today"... Second Post-Adjustment Talks Between Samsung Electronics Labor and Management Extended Until the 19th
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
During this period, the operating loss increased by 12.53% to 65 billion KRW, and the net loss for the period expanded by 12.36% to 66.9 billion KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
